Neurizon Therapeutics this week disclosed new preclinical data for its lead ALS candidate NUZ-001 that the company will present at the BIO International Convention 2026. …
Neurizon presents new mechanistic evidence that NUZ-001 restores proteostasis and supports ALS resilience
June 24, 2026 Australian Biotech
Latest Video
New Stories
-
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News -
Neurizon presents new mechanistic evidence that NUZ-001 restores proteostasis and supports ALS resilience
June 24, 2026 - - Australian Biotech -
Avecho interim review clears path to complete pivotal Phase 3 insomnia trial
June 24, 2026 - - Australian Biotech -
UQ drug QED-203 moves toward first in human trials with Ellison Medical Institute backing
June 24, 2026 - - Australian Biotech -
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 - - Latest News -
Tax deal delays NDIS overhaul and reopens scrutiny with inquiry extension
June 24, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News